Abstract
Purpose
This research investigated the degree and predictors of hot flashes and hypogonadism symptoms in patients with prostate cancer receiving hormone replacement therapy.
Methods
The subjects were 111 patients with prostate cancer receiving hormone replacement therapy in two university hospitals located in D city. The measurement tools included Hot Flash Diary and AMS (Aging Male's Symptoms rating scales). The data were analyzed using t-test, ANOVA, and binary logistic regression analysis.
Results
The percentage of patients who experienced hot flashes among the participants was 14.4%. The predictors for hot flashes were eating irregularly, having coffee frequently and the types of hormone. The average score of hypogonadism symptom was 2.16 out of five-point scale and the highest score of hypogonadism symptom was the sexual symptoms (2.77 out of five-point scale). The predictors for hypogonadism symptom were eating habits and years of having the illness.
REFERENCES
Akaza H.2004. Advanced prostate cancer treatment guidelines: A global perspective; trends of hormone therapy in Japan. British Journal of Urology International. 94(3):5.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Baber R.., Hickey M.., Kwik M.2005. Therapy for menopausal symptoms during and after treatment for breast cancer: Safety considerations. Drug Safety. 28(12):1085––1100.
Carr M. C.2003. The emergence of the metabolic syndrome with menopause. The Journal of Clinical Endocrinology and Metabolism. 88(6):2404––2411.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Choi H. C.., Cho B. L.., Oh B. J.., Kim H. S.2011. Physical activity and exercise for men with late onset hypogonadism. Korean Association of Medical Journal Editors. 29(3):181––190.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Cochran C. J.., Gallicchio L.., Miller S. R.., Zacur H.., Flaws J. A.2008. Cigarette smoking, androgen levels, and hot flushes in midlife women. Obstetrics and Gynecology. 112(5):1037––1044.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Daig I.., Heinemann L. A.., Kim S.., Leungwattanakij S.., Badia X.., Myon E., et al. 2003. The Aging Males' Symptoms (AMS) scale: Review of its methodological characteristics. Health and Quality of Life Outcomes. 1(77):1––12.
Dormire S. L.., Reame N.2003. Hot flash variation in response to experimental manipulation of blood glucose in menopausal women. Nursing Research. 52(5):338––343.
Dormire S.., Howharn C.2007. The effect of dietary intake on hot flashes in menopausal women. Journal of Obstetric, Gynecologic, and Neonatal Nursing. 36(3):255––262.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Engstrom C. A.2008. Hot flashes in prostate cancer: State of the science. American Journal of Men's Health. 2(2):122––132.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Freeman E. W.., Sherif K.2007. Prevalence of hot flushes and night sweats around the world: A systematic review. Climacteric. 10(3):197––214.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Frisk J.2010. Managing hot flushes in men after prostate cancer: A systematic review. Maturitas. 65(1):15––22.
Gold E. B.., Colvin A.., Avis N.., Bromberger J.., Greendale G. A.., Powell L., et al. 2006. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of women's health across the nation. American Journal of Epidemiology. 96(7):1226––1235.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Gold E. B.., Sternfeld B.., Kelsey J. L.., Brown C.., Mouton C.., Reame N., et al. 2000. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. American Journal of Epidemiology. 152(5):463––473.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Greendale G. A.., Gold E. B.2005. Lifestyle factors: Are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy? The American Journal of Medicine. 118(Suppl 12B):148––154.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Grunfeld E. A.., Halliday A.., Martin P.., Drudqe-Coates L.2012. Andropause syndrome in men treated for metastatic prostate cancer. Cancer Nursing. 35(1):63––69.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Hanisch L. J.., Gooneratne N. S.., Soin K.., Gehrman P. R.., Vaughn D. J.., Coyne J. C.2011. Sleep and daily functioning during androgen deprivation therapy for prostate cancer. European Journal of Cancer Care. 20(4):549––554.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Hankinson S. E.., Willett W. C.., Manson J. E.., Hunter D. J.., Colditz G. A.., Stampfer M. J.1995. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. Journal of the National Cancer Institute. 68(17):1297––1302.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Heinemann L. A.., Zimmermann T.., Vermeulen A.., Thiel C.1999. A new ‘Aging Male's Symptoms' (AMS) rating scale. The Aging Male. 2(2):105––114.
Jun S. S.., Kim D. H.., Kim M. Y.2010. Sleep disturbance in prostate cancer patients. The Korean Journal of Fundamentals of Nursing. 17(2):169––176.
Jung G. H.., Suh H. S.., Kim K. G.., Hwang I. C.., Lee K. S.2009. Factors Which May Influence Vasomotor Symptoms in Menopausal and Perimenopausal Women. The Journal of the Korean Society of Menopause. 15(3):164––171.
Jung S. K.., Kim D. I.2008. Clinical trial to evaluate the hot flush relief efficacy and safety of Yiseontanggami in climacteric women with hot flushes. The Journal Of Oriental Gynecology. 21(3):75––89.
Kandiah J.., Amend V.2010. An exploratory study on perceived relationship of alcohol, caffeine, and physical activity on hot flashes in menopausal women. Health. 2(9):989––996.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Kaplan M.., Mahon S.., Cope D.., Keating E.., Hill S.., Jacobson M.2011. Putting evidence in to practice: Evidence-based interventions for hot flashes resulting form cancer therapies. Clinical Journal of Oncology Nursing. 15(2):149––157.
Kim S. K.., Sunwoo J. G.2007. The analysis of the dietary factors related to climacteric symptoms in middle-aged women. The Korean Society of Community Nutrition. 12(1):25––39.
Kim T. S.., Kang S. H.., Rhew H. Y.2009. Efficacy of androgen deprivation therapy in patients with clinically localized prostate cancer. Korean Journal of Urology. 50(11):1073––1077.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Lee J. O.., Kang S. G.., Kim S. H.., Park S. J.., Song S. W.2011. The relationship between menopausal symptoms and heart rate variability in middle aged women. Korean Journal of Family Medicine. 32(5):299––305.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Loblaw D. A.., Virgo K. S.., Nam R.., Somerfield M. R.., Ben-Josef E.., Mendelson D. S., et al. 2007. Initial hormonal management of androgen sensitive metastatic, recurrent, or progressive prostate cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology. 25(12):1596––1605.
National Cancer Information Center. 2013. 2010 Cancer incidence rate & treatment and side effects of prostate cancer. April 29, 2013 cited,. http://www.cancer.go.kr.
Oncology Nursing Society. 2013. ONS PEP -putting evidence into practice: Hot flashes. Nov 16, 2013 cited. http://www.ons/org.
Pimenta F.., Leal I.., Maroco J.., Ramos C.2011. Perceived control, lifestyle, health, socio-demographic factors and menopause: Impact on hot flashes and night sweats. Maturitas. 69(4):338––342.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Sievert L. L.., Morrison L.., Brown D. E.., Reza A. M.2007. Vasomotor symptoms among Japanese-American and European-American women living in Hilo, Hawaii. Menopause. 14(2):261––269.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Sim J. E.., Paik H. Y.., Moon H. K.2007. Breakfast consumption pattern, diet quality and health outcomes in adults from 2001 national health and nutrition survey. The Korean Journal Nutrition. 40(5):451––462.
Tan R. S.., Philip P. S.1999. Perceptions of and risk factors for andropause. Archives of Andrology. 43(3):227––233.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Yun M. H.., Kim H. J.2011. A study on relations among general characteristics, lifestyle habits, and menopausal symptoms measurement indicators during treatment for hot flush in menopausal women. The Journal of Oriental Obstetrics & Gynecology. 24(4):114––125.
Yun M. H.., Yu S. J.., Kim H. J.2011. A study on relations between hot flush and the Kupperman's Index, MENQOL, MRS during treatment for hot flush in menopausal women. The Journal of Oriental Obstetrics & Gynecology. 24(1):87––98.
Table 1.
Characteristics of Prostate Cancer Patients Receiving Hormone Therapy with Hot Flashes (N=16)
Table 2.
Characteristics of Prostate Cancer Patients Receiving Hormone Therapy with Hypogonadism Symptoms (N=111)
Table 3.
Hot Flashes and Hypogonadism Symptoms according to General Characteristics in Prostate Cancer Patients Receivin Hormone Therapy (N=111
Characteristics | Categories | Hot flashes | DTS | |||
---|---|---|---|---|---|---|
Yes (n=16) | No (n=95) | x2 (p†) | M±SD | t or F (p) Scheffé | ||
n (%) | n (%) | |||||
Age (year) | 60~69 | 5 (31.2) | 16 (16.8) | 2.62 | 2.42±0.61 | 2.32 |
70~79 | 9 (56.3) | 53 (55.8) | (.263) | 2.13±0.67 | (.103) | |
80~89 | 2 (12.5) | 26 (27.4) | 2.02±0.65 | |||
M±SD | 75.2±6.71 | |||||
Body Mass Index | Normal weight | 8 (50.0) | 41 (43.2) | 0.43 | 2.15±0.60 | 0.72 |
Overweight | 4 (25.0) | 31 (32.6) | (.888) | 2.08±0.74 | (.488) | |
Obesity | 4 (25.0) | 23 (24.2) | 2.28±0.67 | |||
Spouse | Have | 13 (81.3) | 77 (81.1) | 2.28 | 2.20±0.66 | 1.36 |
Have not | 3 (18.7) | 18 (18.9) | (.319) | 1.98±0.68 | (.176) | |
Education lever | ≤Elementary school | 3 (18.7) | 28 (29.5) | 0.88 | 2.13±0.56 | 0.32 |
Middle school | 6 (37.5) | 28 (29.5) | (.701) | 2.11±0.73 | (.720) | |
≥High school | 7 (43.8) | 39 (41.0) | 2.22±0.69 | |||
Religion | Protestant & catholic | 4 (25.0) | 21 (22.1) | 1.28 | 2.09±0.78 | 0.17 |
Buddhism | 7 (43.8) | 31 (32.6) | (.510) | 2.19±0.66 | (.839) | |
None | 5 (31.2) | 43 (45.3) | 2.17±0.62 | |||
Smoking status | Smoker | 4 (25.0) | 15 (15.8) | 0.81 | 2.35±0.69 | 1.35 |
Nonsmoker | 12 (75.0) | 80 (84.2) | (.471) | 2.12±0.65 | (.178) | |
Drinking status (1 week) | Rare | 9 (56.3) | 66 (69.5) | 1.61) | 2.07±0.63 | 2.35) |
≤1 time | 5 (31.2) | 18 (18.9) | (.450) | 2.41±0.75 | (.100) | |
≥2 times | 2 (12.5) | 11 (11.6) | 2.21±0.64 | |||
Eating habits | Regular | 11 (68.8) | 69 (72.6) | 6.92 | 2.04±0.63 | 16.20 |
Average | 2 (12.5) | 24 (25.3) | (.029) | 2.34±0.64 | (<.001) | |
Irregular | 3 (18.7) | 2 (2.1) | 3.16±0.30 | a>b, c | ||
Nutrition | Balance | 10 (62.5) | 36 (37.9) | 3.14 | 2.09±0.67 | 1.75 |
Average | 5 (31.3) | 43 (45.3) | (.217) | 2.29±0.59 | (.178) | |
Unbalance | 1 (6.2) | 16 (16.8) | 1.98±0.80 | |||
Feeding habit | Vegetarian | 9 (56.3) | 34 (35.8) | 2.41 | 2.33±0.66 | -2.17 |
A meat-eater | 7 (43.7) | 61 (64.2) | (.166) | 2.05±0.63 | (.032) | |
Taste preference | Evenly among all | 10 (62.5) | 61 (64.3) | 0.49 | 2.10±0.68 | 0.74 |
Sweetness | 4 (25.0) | 18 (18.9) | (.855) | 2.22±0.62 | (.476) | |
The others | 2 (12.5) | 16 (16.8) | 2.31±0.66 | |||
Water intake (1 day) | <1 L | 5 (31.2) | 36 (37.9) | 1.78 | 2.22±0.58 | 2.73 |
1~2 L | 7 (43.8) | 47 (49.5) | (.396) | 2.03±0.68 | (.070) | |
>2 L | 4 (25.0) | 12 (12.6) | 2.45±0.74 | |||
Coffee intake (1 day) | ≤1 cup | 4 (25.0) | 56 (59.0) | 8.09 | 2.12±0.66 | 1.12 |
2 cups | 5 (31.2) | 24 (25.2) | (.013) | 2.09±0.71 | (.329) | |
≥3 cups | 7 (43.8) | 15 (15.8) | 2.35±0.61 | |||
Regular exercise (1 week) | <3 times | 5 (31.2) | 25 (26.3) | 0.16 | 2.05±0.58 | -1.01 |
≥3 times | 11 (68.8) | 70 (73.7) | (.762) | 2.20±0.69 | (.314) | |
Duration of treatment since diagnosis (year) | <1 | 9 (56.3) | 37 (38.9) | 1.52 | 2.01±0.63 | 3.50 |
1~5 | 5 (31.2) | 41 (43.2) | (.457) | 2.18±0.64 | (.033) | |
>5 | 2 (12.5) | 17 (17.9) | 2.48±0.70 | a<c | ||
Duration of hormone therapy (year) | <1 | 10 (62.5) | 47 (49.5) | 0.93 | 2.05±0.64 | -1.84 |
≥1 | 6 (37.5) | 48 (50.5) | (.422) | 2.28±0.68 | (.068) | |
Kinds of hormones | LHRH agonist | 14 (87.5) | 50 (52.6) | 0.68 | 2.22±0.65 | 1.10 |
Antiandrogen | 2 (12.5) | 45 (47.4) | (.012) | 2.08±0.69 | (.272) | |
Additional treatment | No | 10 (62.5) | 56 (59.0) | 1.69 | 2.21±0.69 | 0.50 |
Yes | 4 (25.0) | 16 (16.8) | (.417) | 2.04±0.65 | (.606) | |
Operation radiotherapy | y 2 (12.5) | 23 (24.2) | 2.13±0.61 |
Table 4.
Influencing Factors of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy by Binary Logistic Regression Analysis (N=111)